Q-omics provides the consensus-scored RPS20P12 profile across patient tissues and cancer cell-line models. RPS20P12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPS20P12 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPS20P12 RNA expression shows 6,483 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, KIRC, and BRCA as cancer lineages where RPS20P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS20P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS20P12 survival associations across molecular data types. RPS20P12 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS20P12 RNA expression–survival associations across cancer types. High RPS20P12 expression shows unfavorable associations in STAD, ACC, UCEC, PAAD and UVM, but favorable associations in BLCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify STAD as the clearest survival context for RPS20P12 RNA expression.
This table summarizes RPS20P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS20P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS20P12 shows lower tumor expression in PAAD and LUSC and higher tumor expression in KIRC, BLCA, LUAD and HNSC. The KIRC box plot shows higher RPS20P12 RNA expression in tumor versus normal tissue (log2 FC = +0.211, t-test p < 0.001).
This table shows molecular features associated with RPS20P12 in patient tissues and cancer cell lines. In patient samples, RPS20P12 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
